Search Results
Your search for The A,The A matches 32360 pages
Showing 26351 - 26400Aspirin Use Not Associated With Survival in PIK3CA-Mutant Colorectal Cancer
Contrary to emerging data from other studies, the regular use of aspirin was not associated with improved survival in patients with PIK3CA-mutant metastatic colorectal cancer in a study reported at the 2014 Gastrointestinal Cancers Symposium in San Francisco.1 Large Dataset “We did not validate...
Colorectal Cancer Screening: Quality Measures Should Focus on Patient Benefit Over Age Alone, Study Reports
Screening for colorectal cancer based on age alone may contribute to both underuse and overuse of colonoscopy, sigmoidoscopy, and fecal occult blood testing among older people, according to a study by investigators at the University of Michigan and the Veterans Affairs Center for Clinical...
Expert Point of View: Thomas W. Flaig, MD
This study has the potential to expand the number of patients who can benefit from organ-sparing therapy,” said Thomas W. Flaig, MD, Associate Professor in the Division of Medical Oncology at the University of Colorado Denver, commenting on the pooled analysis of RTOG 9906 and 0233 presented at the ...
Fine-Tuning Bladder-Preservation Trimodality Therapy for Patients With Muscle-Invasive Bladder Cancer
Organ preservation is a hallmark of progress in the world of cancer management. For patients with muscle-invasive bladder cancer, the bladder-sparing approach is a well-established alternative to radical cystectomy. Patients undergo cystoscopic evaluation between the induction and consolidation...
Five Key Studies in Prostate Cancer and Renal Cell Carcinoma
The 10th Genitourinary Cancers Symposium, sponsored by ASCO, the American Society for Radiation Oncology, and the Society of Urologic Oncology, was held January 29–February 1, 2014, in San Francisco. The more than 630 abstracts presented addressed essential research in genitourinary malignancies,...
Role of Immunotherapy Explored in Metastatic Castration-Resistant Prostate Cancer
Ipilimumab (Yervoy) failed to meet the primary endpoint of improving overall survival in the randomized, phase III CA184-043 trial. However, the immunotherapy did improve progression-free survival and prostate-specific antigen (PSA) response compared with placebo in postdocetaxel metastatic...
SIDEBAR: Examples of Advances Attributed to Cooperative Group Trials
Produced long-term survival and cures in the majority of pediatric cancer cases Showed that breast-conserving lumpectomy is often a better surgical option than radical mastectomy, developed optimal adjuvant chemotherapy regimens, and demonstrated the preventive benefits of tamoxifen...
The Evolution of U.S. Cooperative Group Trials: Publicly Funded Cancer Research at a Crossroads
Over the past 5 decades, National Cancer Institute (NCI) Clinical Trials Cooperative Groups have played an enormous role in the fight against cancer, tackling a broad social agenda, including cancer prevention, quality-of-life issues for patients with cancer, and comparison of benefits among...
I Refuse to Capitulate to Cancer
Early last year, just as I returned to my residency in neurologic surgery at Stanford University after completing 2 years of my postdoctoral fellowship in a laboratory developing optogenetic techniques, I started losing weight—dropping from 180 lb to 160 lb in just 6 months—and I was having fairly...
State-of-the-Art Update on Prostate Cancer
The 2014 Genitourinary Cancers Symposium, held in San Francisco from January 29 to February 1, brought together more than 3,100 participants from around the world involved in the care of patients with genitourinary malignancies. The abstract presentations and plenary discussions offered the latest...
Greatly Frustrated by Congressional Failure to Act on Sustainable Growth Rate
The American Society of Clinical Oncology (ASCO) is deeply frustrated by the failure of Congress to permanently repeal the flawed sustainable growth rate (SGR) formula used to set Medicare physician payments and passage of the 17th patch to the system. ASCO and the entire physician community worked ...
Transition From Busy Oncologist to Retiree: Challenges and Opportunities
Oncology is a demanding field that requires special qualities to care for very sick patients, many of whom will die prematurely of their disease. Research indicates that years of facing life-and-death decisions in the clinic can be associated with oncology burnout syndrome, which effects physician...
Bendamustine/Rituximab May Be Important Alternative for Indolent NHL or MCL
Results from the BRIGHT study combined with long-term safety data from other studies suggest that bendamustine (Treanda) plus rituximab (Rituxan) “may be an important alternative treatment option” for the initial treatment of patients with low-grade non-Hodgkin lymphoma (NHL) and mantle cell...
Adding Idelalisib to Rituximab Improved Survival in Patients With Relapsed CLL
Receiving rituximab (Rituxan) with idelalisib, rather than rituximab with placebo, “significantly improved progression-free survival, response rate, and overall survival” among patients with relapsed chronic lymphocytic leukemia (CLL) who were less able to undergo chemotherapy because of clinically ...
Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase Chronic Myeloid Leukemia
Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to long-term results of a randomized phase III study. The CA180-034 study also found that early molecular and...
Breast Reconstruction Has Increased Over Time but Varies Widely by Region
Analysis of data from 20,560 women undergoing mastectomy for breast cancer found that breast reconstruction use “increased from 46% in 1998 to 63% in 2007 (P< .001), with increased use of implants and decreased use of autologous techniques over time (P < .001),” according to a report...
City of Hope Names Yuman Fong, MD, Chair, Department of Surgery
City of Hope recently announced the appointment of two new chairs in the Department of Surgery and for the Board of Directors. Yuman Fong, MD, has been named Chair of the Department of Surgery at City of Hope. Dr. Fong comes to City of Hope from Memorial Sloan Kettering Cancer Center in New York,...
USPSTF Appoints New Chair and Co-Vice Chair
The U.S. Preventive Services Task Force recently announced the appointments of Michael L. LeFevre, MD, MSPH, as Chair of the Task Force and Kirsten Bibbins-Domingo, PhD, MD, as Co-Vice Chair. Albert L. Siu, MD, MSPH, current Co-Vice Chair, will remain in his position. Dr. LeFevre and Dr....
American Association for Cancer Research Welcomes New Board of Directors, Nominating Committee Members
The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR Board of Directors for the 2014–2017 term and four members to serve on the Nominating Committee for the 2014–2016 term. They assumed their roles at the AACR Annual Meeting 2014, held in ...
Expect Questions From Patients
Results from the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4), showing that men with early-stage prostate cancer, particularly men under 65 years old, treated with radical prostatectomy had increased survival compared to those assigned to watchful waiting, has raised concerns among...
Prostate Cancer Study Showing Increased Survival for Younger Men Undergoing Prostatectomy Not Expected to Increase Surgeries
Extended follow-up in the Scandinavian Prostate Cancer Group Study Number 4 (SPCG4), reported recently in The New England Journal of Medicine,1 found that men with early-stage prostate cancer, particularly those under 65 years old, who were treated with radical prostatectomy had increased survival...
Have You Heard?
“It’s not a matter of if a child will be seriously poisoned or killed. It’s a matter of when.” Lee Cantrell, PharmD, Director of the San Diego Division of the California Poison Control System and Professor of Clinical Pharmacy at the University of California, San Francisco, commenting on the...
Survivorship: Living Well During and After Cancer
Barrie Cassileth, PhD, Laurance S. Rockefeller Chair in Integrative Medicine and Chief, Integrative Medicine Service, at Memorial Sloan Kettering Cancer Center (MSKCC) in New York has published a new book called Survivorship: Living Well During and After Cancer. Dr. Cassileth provides readers with...
Reishi Mushroom
Scientific name: Ganoderma lucidum Common names: Ling zhi, lin zi, mushroom of immortality Overview A fungus, reishi mushroom is an important component of the traditional medical systems of China, Japan, Korea, and other Asian countries. It is used to increase energy, stimulate the immune system,...
MD Anderson Honors Two Champions for Women in Medicine and Research
Two champions of gender equality in medicine and research were recently honored by The University of Texas MD Anderson Cancer Center. Laurie Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and Provost for Medical Affairs of Cornell University since 2012, received...
Ongoing Clinical Trials Actively Recruiting Adolescent and Young Adult Survivors of Childhood Cancer
ADOLESCENT AND YOUNG ADULT CHILDHOOD CANCER SURVIVORS Study Type: Randomized/interventional Study Title: A Randomized Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer Study Sponsor and Collaborators: St. Jude Children’s Research Hospital Purpose: Five-year...
Lenalidomide Acts in Myeloma by Degrading Lymphoid Transcription Factors IKZF1 and IKZF3
The mechanism of action of lenalidomide (Revlimid) in multiple myeloma and other B-cell neoplasms remains largely uncharacterized. In a study reported in Science, Krönke and colleagues identified one of the effects of lenalidomide in this setting. Use of quantitative proteomics showed that...
shRNAs Can Identify T-Cell Inhibitory Mechanisms in Tumor Microenvironment
Although recent findings indicate that targeting of inhibitory receptors on T cells can produce durable responses in some cancer patients despite the presence of advanced disease, the mechanisms controlling T-cell function in immunosuppressive tumors have not been well characterized. In a study...
Mutation Predicts Benefit From Alkylating Chemotherapy in Oligodendroglial Tumors
Patients in the Radiation Therapy Oncology Group (RTOG) 9402 study with 1p/19q codeleted anaplastic oligodendroglial tumors had markedly prolonged overall survival after chemoradiotherapy (with procarbazine, lomustine, and vincristine) compared with radiation therapy alone. Some patients with...
Antioxidants Accelerate Lung Cancer Progression and Reduce Survival in Mice
Clinical trials of antioxidants in cancer have yielded inconsistent results. In a study reported in Science Translational Medicine, Sayin and colleagues evaluated the effects of the antioxidants N-acetylcysteine and vitamin E in mouse models of BRAF- and KRAS-induced lung cancer. N-acetylcysteine...
Synergy of IAP Antagonist and Demethylating Agents Against AML Stem/Progenitor Cells
In a study reported in the Journal of the National Cancer Institute, Carter and colleagues identified deregulated apoptotic components in acute myeloid leukemia (AML) stem/progenitor cells and investigated the effects of the novel inhibitor of apoptosis (IAP) protein antagonist and SMAC mimetic...
Join the 21st Annual Cancer Survivors’ Celebration Walk & 5K
Nearly 4,000 attendees, including more than 700 cancer survivors along with friends and family members, will gather in Chicago’s Grant Park for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University’s Annual Cancer Survivors’ Celebration Walk & 5K Run. This year’s event will ...
Two Behavioral Interventions Help Cancer Patients Struggling With Sleep Issues, Penn Medicine Study Finds
Patients with cancer who are struggling with sleep troubles, due in part to pain or side effects of treatment, can count on two behavioral interventions for relief—cognitive behavioral therapy for insomnia and mindfulness-based stress reduction—Penn Medicine researchers reported in a recent study...
Yvonne T. Maddox, PhD, Appointed Acting Director of National Institute on Minority Health and Health Disparities
Francis S. Collins, MD, PhD, Director of the National Institutes of Health recently announced the appointment of Yvonne T. Maddox, PhD, as Acting Director of the National Institute on Minority Health and Health Disparities (NIMHHD). This follows the retirement Dr. John Ruffin, NIMHD’s previous...
The FDA’s Bad Ad Program
INSIDE THE BLACK BOX is an occasional column providing insight into the FDA and its policies and procedures. In this installment, Robert Dean, MBA, Director, and Michael Sauers, Deputy Director, of Division II in the FDA’s Office of Prescription Drug Promotion discuss the FDA’s Bad Ad program. The...
American Association for Cancer Research Elects José Baselga, MD, PhD, as President-Elect 2014–2015
The members of the American Association for Cancer Research (AACR) have elected José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center in New York, as their President-Elect for 2014–2015. Dr. Baselga is an internationally recognized physician-scientist whose research...
The CoMMpass Trial in Multiple Myeloma
When I was diagnosed with multiple myeloma in 2008, at just 47, I was lucky. I was asymptomatic, my cancer was detected through a routine blood test, and I had the smoldering type, so I didn’t need immediate treatment. Plus, I knew that recent advances in more effective therapies were making it...
Unraveling the Molecular Complexity of Multiple Myeloma
In 2011, the Multiple Myeloma Research Foundation (MMRF) announced the launch of CoMMpass (Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile), a clinical study at the heart of its Personalized Medicine Initiative. CoMMpass will follow 1,000 newly diagnosed...
Does ‘Specialist Bias’ Contribute to Overtreatment of Prostate Cancer?
Specialist bias, in which specialists recommend the therapy that they are capable of delivering, is thought to influence the treatment of patients with localized prostate cancer and to contribute to overtreatment of men with limited life expectancy,” Ayal A. Aizer, MD, MPH, and colleagues, from the ...
Shaw T. Chen, MD, PhD, Joins Polaris Pharmaceuticals
Shaw T. Chen, MD, PhD, has been appointed Executive Vice-President of Regulatory Affairs at Polaris Pharmaceuticals, a subsidiary of Polaris Group. Dr. Chen had previously been with the U.S. Food & Drug Administration (FDA) for over 26 years in new drug development. Most recently he served as...
William Pao, MD, PhD, Joins Roche to Lead Oncology Research
Roche recently announced that William Pao, MD, PhD, Professor of Medicine and Head of the Hematology-Oncology Division at Vanderbilt University Medical Center, Nashville, will join Roche Pharma Research and Early Development (pRED) as Global Head of the Oncology Disease and Translational Area...
Decision Time for Lung Cancer Screening in High‑Risk Populations
For decades, dedicated members of the oncology community have fought to increase the nation’s focus on lung cancer prevention and treatment. Although smoking cessation initiatives have reduced cigarette consumption, lung cancer 5-year survival has remained stagnant at 15%, lagging far below most...
‘How Am I Doing, Doc?’
The goal of effective adjuvant therapy is to increase overall survival. It has been suggested cynically that all we need to accomplish, actually, is to delay recurrence until after the time the patients die from another cause. However, patients want to hear from us that “it’s never coming back,”...
Study Shows Pathologic Complete Response to Neoadjuvant Therapy for Breast Cancer of Prognostic Value but Not for Use as Surrogate for Survival
Pathologic complete response to neoadjuvant therapy has been proposed as a surrogate endpoint for long-term clinical benefit in breast cancer. The U.S. Food and Drug Administration (FDA) established the international Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) working group to...
Hagop Kantarjian, MD, and Victor Fazio, MD, Named Recipients of 2014 Lifetime Achievement Awards Presented by Castle Connolly Medical Ltd
Hagop Kantarjian, MD, Professor and Chair of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, and Victor Fazio, MD, Chairman Emeritus, Digestive Disease Institute; Department of Colorectal Surgery, Cleveland Clinic, Rochester, were honored recently with the “Lifetime...
Association of Community Cancer Centers Honors Researcher and Community Oncologist With National Award
In recognition of his dedication to cancer research and education, and for promoting the goals of cancer prevention, early detection, and quality cancer treatment, John Powderly II, MD, Certified Physician Investigator, President and Founder of Carolina BioOncology Institute, Huntersville, North...
Awards Presented at Annual Meeting of Society of Interventional Radiology
The Journal of Vascular and Interventional Radiology, the Society of Interventional Radiology’s (SIR) peer-reviewed scientific journal, together with SIR Foundation, recently presented a number of awards at SIR’s 39th Annual Scientific Meeting in San Diego. Clinical Research Eliseo Vano, PhD, an...
ASBMT Honors Mary Horowitz, MD, MS, With Lifetime Achievement Award for Blood and Marrow Transplant Research
Mary Horowitz, MD, MS, the Robert A. Uihlein, Jr. Chair in Hematologic Research, Professor of Medicine and Chief of Hematology and Oncology at the Medical College of Wisconsin (MCW), was presented with the 2014 Lifetime Achievement Award by the American Society for Blood and Marrow Transplantation...
Utah Center for Genetic Discovery to Integrate Genome Data Into Patient Care
The USTAR Center for Genetic Discovery is partnering with California-based Omicia, Inc, to make analyzing a patient’s genome as routine as performing a blood test. The center, codirected by Mark Yandell, PhD, and Gabor Marth, DSc, was launched this month with $6 million from the University of Utah...
Determining Why Younger Women With Breast Cancer Are Less Likely to Survive Than Their Older Counterparts
Although cancer survival rates among pediatric and older adult patients continue to rise, survival rates for adolescents and young adults (AYAs), defined by the National Cancer Institute as those between the ages of 15 and 39, have remained stagnant for decades. In breast cancer especially, AYAs...
